Podocyte Differentiation Protocol Using Segmented Induction Media
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for deriving functional podocytes from pluripotent stem cells are inefficient, time-consuming, and expensive, limiting their application in modeling kidney diseases and therapeutic applications.
Innovation Solution
A feeder-free method involving specific induction media compositions and growth factors such as Activin A, Noggin, GSK3 inhibitors, Wnt3a, FGF9, BMP7, VEGF, and retinoic acid to differentiate human pluripotent stem cells into mature podocytes within 12 days, using culture plates coated with laminin to support cell adhesion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing protocols for deriving podocytes from pluripotent stem cells are used, then functional podocytes can be obtained, but the process is time-consuming and expensive
Solution Approach 1:
The protocol optimizes differentiation parameters including growth factor concentrations (Activin A at 10-100 ng/ml, CHIR99021 at 1-3 μM, FGF9 at 50-200 ng/μl, BMP7 at 50-100 ng/ml), culture durations for each stage (primitive streak: 2-4 days, intermediate mesoderm: 2-3 days, nephron progenitor: 2-3 days, podocyte: 5-7 days), and media compositions to achieve accelerated podocyte differentiation within 12 days while maintaining high efficiency
Solution Approach 2:
The differentiation process is divided into four distinct sequential stages with specific media formulations for each: (a) primitive streak induction medium with Activin A and GSK3 inhibitor, (b) intermediate mesoderm induction medium with GSK3 inhibitor, (c) nephron progenitor induction medium with FGF9 and heparin, (d) podocyte induction medium with BMP7, VEGF, and retinoic acid. This segmented approach enables precise control over differentiation timing and efficiency
2Reliability
If existing protocols for deriving podocytes from pluripotent stem cells are used, then functional podocytes can be obtained, but the cost is high due to expensive media components
Solution Approach 1:
The protocol specifies optimized concentrations of growth factors and media components that balance cost and efficacy: Activin A (10-100 ng/ml), CHIR99021 (1-3 μM), FGF9 (50-200 ng/μl), BMP7 (50-100 ng/ml), VEGF (25-50 ng/ml), and retinoic acid (0.1-1.0 μM). These parameter optimizations reduce media costs while maintaining high podocyte differentiation efficiency
Solution Approach 2:
The protocol uses feeder-free culture conditions with laminin-coated plates instead of expensive feeder layers, and employs defined media compositions that can be prepared cost-effectively, eliminating the need for costly serum-containing media while achieving reliable podocyte differentiation
3Productivity
If accelerated differentiation is attempted, then time is reduced, but differentiation efficiency and podocyte maturity may be compromised
Solution Approach 1:
The protocol includes preliminary assessment steps at each differentiation stage to ensure proper progression before advancing to the next stage: MIXL1 expression assessment after primitive streak induction, PAX8 and GATA3 expression assessment after intermediate mesoderm formation, and SIX2/CITED1 expression assessment after nephron progenitor generation. This ensures podocyte maturity and functionality are maintained despite accelerated timing
Solution Approach 2:
The protocol maintains optimal growth factor concentrations and culture conditions throughout the accelerated 12-day process, including specific dosages of Activin A, CHIR99021, FGF9, BMP7, VEGF, and retinoic acid at each stage, ensuring that podocyte differentiation proceeds rapidly while achieving full maturation and functional competence
Data Source
AI summary
Disclosed herein is a method for producing intermediate mesodermal cells from human pluripotent stem cells. Also disclosed is a method for producing nephron progenitor cells from human pluripotent stem cells. Also disclosed is a method for producing podocytes. Also disclosed is a method for treating a kidney disease in a subject, that involves administering to the subject a therapeutically effective amount of the produced intermediate mesodermal cells, nephron progenitor cells, and/or podocytes.